

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

Nkx-2.5 (A-3)

RRID:AB_11149571

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-376565, RRID:AB_11149571

Antibody Information

URL: http://antibodyregistry.org/AB_11149571

Proper Citation: Santa Cruz Biotechnology Cat# sc-376565, RRID:AB_11149571

Target Antigen: Nkx-2.5 (A-3)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Immunofluorescence; ELISA; Western Blot; Immunoprecipitation; WB, IP, IF, ELISA

Antibody Name: Nkx-2.5 (A-3)

Description: This monoclonal targets Nkx-2.5 (A-3)

Target Organism: rat, mouse, human

Antibody ID: AB_11149571

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-376565

Record Creation Time: 20250820T000040+0000

Record Last Update: 20250820T070558+0000

Ratings and Alerts

No rating or validation information has been found for Nkx-2.5 (A-3).

No alerts have been found for Nkx-2.5 (A-3).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Sun W, et al. (2024) Generation of a TAB2 knockout hESC line (WAe009-A-Z) derived from H9 using CRISPR/Cas9. Stem cell research, 74, 103284.

Hua C, et al. (2024) Generation of a human induced pluripotent stem cell line ZZUNEUi030-A from a female patient carrying a heterozygous CALM2 (c.395 A > T) mutation. Stem cell research, 81, 103515.

Lu F, et al. (2023) Generation of a FLNA knockout hESC line (WAe009-A-P) to model cardiac valvular dysplasia using CRISPR/Cas9. Stem cell research, 71, 103162.

Bai J, et al. (2023) Generation of a TRPM8 knockout hESC line (WAe009-A-A) derived from H9 using CRISPR/Cas9. Stem cell research, 67, 103040.

Dong Y, et al. (2022) Generation of an iPSC line (ZZUNEUi021-A) from a hypertrophic cardiomyopathy patient with TNNT2 mutation. Stem cell research, 58, 102622.

Cheng D, et al. (2022) An integration-free iPSC line ZZUNEUi028-A derived from a patient with hypertrophic cardiomyopathy carrying a heterozygous mutation (c. 1504 C > T) in MYBPC3 gene. Stem cell research, 63, 102848.

Zhao X, et al. (2022) A heterozygous MYBPC3 (c. 772+1G > A) mutant human induced pluripotent stem cell line (ZZUNEUi025-A) generated from a male patient with hypertrophic cardiomyopathy. Stem cell research, 60, 102722.

Zhao J, et al. (2022) Human induced pluripotent stem cell line ZZUNEUi027-A generated from a long QT syndrome patient with a heterozygous KCNH2 (c. 128 A > G) mutant. Stem cell research, 63, 102836.

Ding T, et al. (2022) Reprogramming of a human induced pluripotent stem cell line (ZZUSAHi004-A) from a long QT syndrome patient with a heterozygous AKAP9 (c. 4021C > A) mutant. Stem cell research, 65, 102966.

Lan Y, et al. (2021) Stage-specific regulation of DNA methylation by TET enzymes during human cardiac differentiation. Cell reports, 37(10), 110095.

Li X, et al. (2021) A heterozygous TTN (c. 79,684C>T) mutant human induced pluripotent stem cell line (ZZUNEUi023-A) generated from a Kazakh patient with dilated cardiomyopathy. Stem cell research, 57, 102614.

Zhang JZ, et al. (2019) A Human iPSC Double-Reporter System Enables Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug Response Profiles. Cell stem cell, 24(5), 802.